Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04467996
Other study ID # 19-3070
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date October 19, 2020
Est. completion date December 31, 2023

Study information

Verified date December 2022
Source Denver Health and Hospital Authority
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Intrauterine balloon tamponade (IUBT) is recommended worldwide as the second-line therapy to treat postpartum hemorrhage. While much literature demonstrates the effectiveness of this therapy, little is known about how long the IUBT should be used once placed. Though it is common to use IUBT for 12-24 hours, the balloon may be equally effective when used for shorter durations of time, which could have beneficial effects for patients and hospitals. The proposed study is a pragmatic randomized controlled trial of non-inferiority comparing two durations of time for intrauterine balloon tamponade placement, 6 and 18 hours, in controlling postpartum hemorrhage. The specific aims of the proposed study are to determine: 1) whether quantitative blood loss significantly differs when the balloon is removed in 6 hours compared to 18 hours, 2) whether hemorrhage-related morbidity differs when the IUBT is kept in place for 6 or 18 hours, and 3) whether shorter duration of IUBT placement has beneficial effects including shortened postpartum hospital stays, improved maternal-infant bonding, and reduced postpartum pain prior to maternal discharge from hospital. We hypothesize that, once hemorrhage control has been achieved with IUBT placement, there is no clinically significant difference in postpartum blood loss when the balloon is removed 6 hours after placement compared to 18 hours after placement.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 64
Est. completion date December 31, 2023
Est. primary completion date November 1, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Women at Denver Health and Hospital Authority (DHHA) who have an IUBT placed for postpartum hemorrhage due to uterine atony will be approached for enrollment in the study. Exclusion Criteria: - Women will be excluded from the study if they: are less than 18 years of age; had a cesarean delivery; are unable to consent for themselves; have a preexisting or acquired clotting factor disorder such as von Willebrand or hemophilia, disseminated intravascular coagulation, or therapeutic anticoagulation at time of delivery; would refuse blood product transfusion; have a fetal demise or birth of a previable fetus; or are incarcerated at the time of delivery. Women who do not speak English or Spanish will be offered enrollment if a phone interpreter is available to review the consent, but will be excluded from the survey portion of the study.

Study Design


Intervention

Device:
Intrauterine balloon tamponade
Intrauterine balloon will be placed in the uterus for postpartum hemorrhage control.

Locations

Country Name City State
United States Denver Health Hospital Denver Colorado

Sponsors (1)

Lead Sponsor Collaborator
Denver Health and Hospital Authority

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Quantitative blood loss total blood loss includes output from the intrauterine balloon plus blood loss from sanitary pads 18 hours
Secondary Postpartum hemorrhage related outcomes return to the OR, replacement of the IUBT, hysterectomy, pelvic artery embolization during admission
Secondary Hematocrit change in hematocrit from admission to discharge during admission
Secondary Postpartum length of stay Length of stay in hours during admission
Secondary Endometritis diagnosed postpartum during admission
Secondary Chorioamnionitis requiring more than one dose of antibiotics postpartum during admission
Secondary Transfusion of packed red blood cells after IUBT placement during admission
Secondary Maternal-infant bonding measured by the mother-to-infant bonding scale (MIBS), scale 0-27, higher score indicates worse maternal-infant bonding during admission
Secondary Maternal pain measured by the visual analogue scale (VAS), scale 0-10, higher score indicates worse pain during admission